Combination treatment for arsenic-resistant APL
Part of Cancer clinical trials.
This trial tests if combining interferon-α with arsenic trioxide (ATO) can help people whose acute promyelocytic leukemia (APL) has stopped responding to arsenic treatment. If you have this type of leukemia that came back or didn't get better after arsenic therapy, this study may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a specific type of leukemia called APL, confirmed by a genetic test (PML-RARα).
- Your leukemia has come back (or had a molecular relapse) after prior arsenic treatment, and did not get better with standard treatment.
- You are in fairly good health otherwise, with a performance status score of 0-2.
- You do not have serious heart, liver, kidney, or autoimmune conditions, active infections (like hepatitis or HIV), or epilepsy.
- You are not pregnant or breastfeeding, and you are not taking part in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a combination of tretinoin (ATRA) and arsenic trioxide (ATO)—with or without another antibody-like drug called gemtuzumab—treats people with newly diagnosed acute promyelocytic leukemia (APL). The goal is to see if these medicines work better together and are safe.
This trial tests a combination of oral arsenic and ATRA for people newly diagnosed with acute promyelocytic leukemia (APL). It aims to see if this drug combo can treat the disease effectively without standard chemotherapy.
This trial tests whether an oral version of arsenic trioxide works as well as the IV version for people with a certain type of leukemia called APL. It aims to confirm that taking the drug by mouth has similar safety and effectiveness.
This Phase 2 study tests an oral form of arsenic trioxide in people newly diagnosed with APL (a specific leukemia subtype). It aims to see how well this frontline treatment works and whether it can be given safely.
This Phase 2 study tests a treatment approach for children and teens newly diagnosed with acute promyelocytic leukemia (APL) that is confirmed by a specific lab genetic change. It may help improve outcomes, but it requires meeting several safety and test-confirmation criteria.
This trial studies whether a combination medicine (ATO plus ATRA) is safe and works better in people with a specific type of AML (acute myeloid leukemia) caused by an NPM1 mutation. You would join only after your leukemia has reached remission, meaning the active leukemia has cleared after initial treatment.
Hear when a new Tumour trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.